Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4741 AL 4755

A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease

Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL.

J Am Med Dir Assoc. 2016 Feb;17(2):142-7. doi: 10.1016/j.jamda.2015.08.019. Epub 2015 Oct 9.

Neurorestoratologic Strategies and Mechanisms in the Nervous System

Chen L, Ao Q, Sharma HS, Wang A, Feng S.

Biomed Res Int. 2015;2015:163170. doi: 10.1155/2015/163170. Epub 2015 Sep 29.

The impact of ginsenosides on cognitive deficits in experimental animal studies of Alzheimer's disease: a systematic review

Sheng C, Peng W, Xia ZA, Wang Y, Chen Z, Su N, Wang Z.

BMC Complement Altern Med. 2015 Oct 24;15:386. doi: 10.1186/s12906-015-0894-y.

Interpretation of mushroom as a common therapeutic agent for Alzheimer's disease and cardiovascular diseases

Rahman MA, Abdullah N, Aminudin N.

Crit Rev Biotechnol. 2016 Dec;36(6):1131-1142. doi: 10.3109/07388551.2015.1100585. Epub 2015 Oct 30.

Benefits and risks of add-on therapies for Alzheimer's disease

Magierski R, Sobow T.

Neurodegener Dis Manag. 2015 Oct;5(5):445-62. doi: 10.2217/nmt.15.39. Epub 2015 Oct 30.

Memantine ER/Donepezil: A Review in Alzheimer's Disease

Greig SL.

CNS Drugs. 2015 Nov;29(11):963-70. doi: 10.1007/s40263-015-0287-2.

Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease

Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G.

Neurochem Int. 2016 May;95:63-74. doi: 10.1016/j.neuint.2015.10.011. Epub 2015 Oct 31.

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies

Schroeder SK, Joly-Amado A, Gordon MN, Morgan D.

J Neuroimmune Pharmacol. 2016 Mar;11(1):9-25. doi: 10.1007/s11481-015-9637-6. Epub 2015 Nov 4.

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease

Wicke K, Haupt A, Bespalov A.

Expert Opin Investig Drugs. 2015;24(12):1515-28. doi: 10.1517/13543784.2015.1102884. Epub 2015 Nov 7.

Tau Immunotherapy

Sigurdsson EM.

Neurodegener Dis. 2016;16(1-2):34-8. doi: 10.1159/000440842. Epub 2015 Nov 10.

Alzheimer's Disease: Mechanism and Approach to Cell Therapy

Amemori T, Jendelova P, Ruzicka J, Urdzikova LM, Sykova E.

Int J Mol Sci. 2015 Nov 4;16(11):26417-51. doi: 10.3390/ijms161125961.

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease

Maqbool M, Mobashir M, Hoda N.

Eur J Med Chem. 2016 Jan 1;107:63-81. doi: 10.1016/j.ejmech.2015.10.018. Epub 2015 Oct 21.

Developing therapeutic vaccines against Alzheimer's disease

Wisniewski T, Drummond E.

Expert Rev Vaccines. 2016;15(3):401-15. doi: 10.1586/14760584.2016.1121815. Epub 2015 Dec 11.

Basic aspects in selecting a suitable transgenic rodent model for Alzheimer's disease

Balmus IM, Ciobica A, Negura A, Negura L, Anton E.

Psychiatr Danub. 2015 Dec;27(4):338-45.

Current and Future Treatments for Alzheimer Disease

Small GW, Greenfield S.

Am J Geriatr Psychiatry. 2015 Nov;23(11):1101-5. doi: 10.1016/j.jagp.2015.08.006. Epub 2015 Sep 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias